Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 19/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 19/20 | 1.00 |
| ▸ | CHRNG | P07510 | 18/20 | 1.00 |
| ▸ | CHRND | Q07001 | 18/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radafaxine SCHEMBL30486031 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29751668 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29465705 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453827 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL2599138 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL13014841 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL48964 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL14521595 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL5478077 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3154016 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | FANG KEVIN QUN | 2010-05-20 | — | — | US | disclosed |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | FANG KEVIN QUN | 2010-05-20 | — | — | US | disclosed |
| EP-1759701-A2 | Buproprion Metabolites and Methods of Their Synthesis and Use. | Sepracor, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | MAOB, MAOA, HTR5A | CHRNB2 25/4885SLC6A2 6/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.